Anima Biotech is using its protein synthesis monitoring (PSM) platform to develop strategies across multiple therapeutic areas with high unmet needs, including fibrosis, respiratory syncytial virus, oncology and Huntington's disease. Principal PSM Technology Scientist Dr. Wissam Mansour explained: “Our work is focused on translation regulation, looking at small molecules that decrease or increase a target protein’s production. We use a proprietary technology that involves labeling tRNAs with a fluorescent tag, then transfecting signature pairs into the cells of interest. This allows us to visualize and monitor translation of the target protein by studying changes in the resulting FRET signals. By identifying compounds that modulate protein production, we can develop new strategies to help combat diseases that are hard to treat.”

Increased speed and higher throughput

The VIAFLO 96/384 handheld electronic pipette is the ideal solution for laboratories needing an affordable, compact and easy to use pipette that provides increased productivity. Dr. Mansour continued: “During the early stages of assay development, and later on in the hit validation and hit-to-lead phases, we work with small numbers of microplates. In the past, this was done manually using an 8 or 12 channel pipette, a tedious and time consuming process that required multiple transfers as it was not possible to fill 384 wells in one go. We wanted to increase our throughput, and so we invested in a VIAFLO 96/384. The VIAFLO 96/384 allows us to transfer samples and reagents into an entire 384 well plate in one step, reducing the preparation time per plate by 80 percent, increasing the throughput considerably.”